U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics, Inc. , a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that the U.S. Food...

Related Keywords

Italy ,Dirk Thye ,Securities Exchange ,International Cooperative Ataxia Rating Scale Rm ,Drug Administration ,European Medicines Agency ,Quince Therapeutics Inc ,Nasdaq ,Exchange Commission ,Quince Therapeutics ,Investigational New Drug ,Neurologic Effects ,Chief Executive Officer ,Special Protocol Assessment ,New Drug Application ,International Cooperative Ataxia Rating Scale ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Markets ,